This reinforcement mechanism helps humans learn which behaviors are beneficial
Diabetes Res Sci Technol
Reference Ranges: These are based on the general population
While both groups had similar rates of adverse events (89% in the liraglutide group and 88% in the placebo group), the liraglutide group reported a higher incidence of gastrointestinal side effects due to dose escalations, however, none resulted in hospitalization
Professor Patricia Grigson, chair of the Department of Neural and Behavioral Sciences, said: Our results are very promising as GLP-1R agonist treatment appears to be highly protective, but more research is needed to establish a causal relationship between the use of these drugs and decreased risk for severe COVID-19 outcomes in patients with type 2 diabetes. People with diabetes are at a greater risk of severe COVID-19 outcomes, with a recent study highlighting that almost a third of COVID-19-related deaths in England were made up of people with type 2 diabetes
A BMI of 27 or higher , along with having a weight-related issue like high blood pressure, type 2 diabetes, or elevated cholesterol
